Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
5.51
+0.01 (0.18%)
At close: May 12, 2026, 4:00 PM EDT
5.55
+0.04 (0.73%)
After-hours: May 12, 2026, 6:36 PM EDT
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
| Name | Position |
|---|---|
| Dr. Josh Neman-Ebrahim Ph.D. | Chief Clinical Officer |
| Dr. Thomas C. Chen M.D., Ph.D. | Founder, Chief Medical Officer, Chief Scientific Officer & Vice Chairman |
| Mr. Amir Farrokh Heshmatpour | President, CEO, Executive Chairman & Secretary |
| Mr. David Choi Jr. | Chief Accounting Officer |
| Mr. Keithly A. Garnett | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-05 | 10-K/A | neonctechnologies_10ka.htm |
| 2026-04-24 | 8-K | neonctechnologies_8k.htm |
| 2026-04-16 | 8-K | neonctechnologies_8k.htm |
| 2026-04-10 | S-3 | neonctechnologies_s3.htm |
| 2026-04-07 | CORRESP | filename1.htm |
| 2026-04-03 | 8-K | neonctechnologies_8k.htm |
| 2026-04-02 | S-3 | neonctechnologies_s3.htm |
| 2026-03-31 | 10-K | neonctechnologies_10k.htm |
| 2026-03-23 | 8-K | neonctechnologies_8k.htm |
| 2026-03-17 | 8-K | neonctechnologies_8k.htm |